AstraZeneca (LON:AZN) PT Set at GBX 9,000 by Credit Suisse Group

AstraZeneca (LON:AZN) received a GBX 9,000 ($117.59) price objective from Credit Suisse Group in a research note issued on Monday, Borsen Zeitung reports. Credit Suisse Group’s price objective indicates a potential upside of 3.33% from the stock’s current price.

Other research analysts also recently issued research reports about the stock. Jefferies Financial Group set a GBX 9,950 ($130.00) target price on shares of AstraZeneca in a report on Monday, July 12th. The Goldman Sachs Group set a GBX 6,950 ($90.80) price objective on shares of AstraZeneca in a report on Monday, August 9th. JPMorgan Chase & Co. set a £100 ($130.65) price objective on shares of AstraZeneca in a report on Wednesday, September 15th. Morgan Stanley set a £100 ($130.65) price objective on shares of AstraZeneca in a report on Friday, September 17th. Finally, Liberum Capital restated a “buy” rating and set a GBX 9,220 ($120.46) price objective on shares of AstraZeneca in a report on Monday, June 7th. Two analysts have rated the stock with a sell rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat, AstraZeneca currently has a consensus rating of “Buy” and an average price target of GBX 9,501.54 ($124.14).

Shares of AZN opened at GBX 8,710 ($113.80) on Monday. The company has a market capitalization of £134.93 billion and a PE ratio of 41.67. AstraZeneca has a one year low of GBX 6,736 ($88.01) and a one year high of GBX 8,848 ($115.60). The company has a debt-to-equity ratio of 190.47, a current ratio of 1.23 and a quick ratio of 1.01. The company’s fifty day moving average price is GBX 8,398.48 and its 200 day moving average price is GBX 8,012.18.

About AstraZeneca

AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases.

See Also: Dividend Aristocrat Index

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.